Selective Inhibition of Esophageal Cancer Stem-like Cells with Salinomycin

Author(s): Mahdi Zarei, Marie S. Jazi*, Mahboubeh Tajaldini, Ayyoob Khosravi, Jahanbakhsh Asadi.

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 20 , Issue 7 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Targeting Cancer Stem-Like Cells (CSLCs) can provide promising new therapeutic strategies to inhibit cancer progression, metastasis and recurrence. Salinomycin (Sal), an antibacterial ionophore, has been shown to inhibit CSCs specifically. Recently, it has been reported that Sal can destabilize TAZ, the hypo pathway transducer in CSLCs.

Objectives: Here, in the current study, we aimed to assess the differential toxicity of Sal in esophageal CSLCs and its relation to TAZ gene expression.

Methods: The esophageal cancer cell line, KYSE-30, was used for the enrichment of CSLCs. The expression of TAZ was knocked down using specific siRNA transfection and then the cytotoxicity of Sal was measured using XTT assay. The qRT-PCR method was used for gene expression assessment and the sphere formation ability was monitored using light microscopy.

Results: Our findings showed that esophageal CSLCs over-express stemness-associated genes, including SOX2, OCT4 as well as TAZ (~14 fold, P value=0.02) transcription coactivator. We found Sal can selectively inhibit KYSE-30 CSLCs viability and sphere formation ability; however, TAZ knockdown does not change its differential toxicity.

Conclusion: Overall, our results indicated that Sal can selectively decrease the viability of esophageal CSLCs in a TAZ-independent manner.

Keywords: Salinomycin, esophageal cancer stem-like cell, selective toxicity, TAZ knockdown, CSLC, stemness.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 7
Year: 2020
Page: [783 - 789]
Pages: 7
DOI: 10.2174/1871520620666200310093125
Price: $65

Article Metrics

PDF: 9